Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Prevalence of Hepatic Steatosis and Associated Factors in Iranian Patients With Chronic Hepatitis C



Poortahmasebi V1 ; Aleagha MSE2 ; Amiri M3 ; Qorbani M4, 5 ; Farahmand M6 ; Asayesh H7 ; Alavian SM8
Authors
Show Affiliations
Authors Affiliations
  1. 1. Hepatitis B Molecular Laboratory, Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
  2. 2. Department of Clinical Biochemistry, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
  3. 3. Department of Cell Biology and Anatomy, Schulich School of Medicine and Dentistry, Western University, London, ON, Canada
  4. 4. Department of Community Medicine, Alborz University of Medical Sciences, Karaj, Iran
  5. 5. Non-Communicable Disease Research Center, Endocrinology and Metabolism Population Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran
  6. 6. Virology Department, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran
  7. 7. Department of Medical Emergencies, Qom University of Medical Sciences, Qom, Iran
  8. 8. Middle East Liver Diseases (MELD) Center, Tehran, Iran

Source: Medical Journal of the Islamic Republic of Iran Published:2016

Abstract

Background: Hepatic steatosis is commonly observed in patients with chronic hepatitis C (CHC). Many studies indicate a relationship between steatosis and fibrosis progression. The aim of this study was to analyze the prevalence of hepatic steatosis and related factors in Iranian CHC patients. Methods: One hundred and fifteen consecutive patients with CHC were enrolled which were treatment- naive. The patients were divided into groups with and without steatosis according to the result of liver biopsy (58.3% and 41.7%, respectively). Demographic, histological, biochemical and virological factors were examined and compared in all patients. Results: In terms of host factors, body mass index (BMI), triglyceride, fasting blood glucose (FBG), necroinflammatory activity and severity in fibrosis of CHC patients with steatosis was significantly higher than the patients without steatosis. Of viral factors, HCV viral load was not significantly altered in patients with steatosis. Moreover, HCV genotypes did not meet such association. Using multivariate regression analysis, parameters of BMI values, FBG level and stage of fibrosis were independently associated with steatosis. Conclusion: Our data indicate that CHC patients are more susceptible to development of hepatic steatosis. Based on our results, grade of steatosis appears to be associated with hepatic fibrosis progression rate in CHC patients.